ABVC BioPharma (NASDAQ:ABVC) Shares Up 2.6% – Should You Buy?
by Teresa Graham · The Cerbat GemABVC BioPharma, Inc. (NASDAQ:ABVC – Get Free Report)’s stock price rose 2.6% during mid-day trading on Monday . The company traded as high as $1.6129 and last traded at $1.57. Approximately 183,346 shares traded hands during trading, an increase of 38% from the average daily volume of 133,089 shares. The stock had previously closed at $1.53.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded ABVC BioPharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.
View Our Latest Stock Analysis on ABVC BioPharma
ABVC BioPharma Trading Up 12.0%
The business’s 50 day simple moving average is $1.23 and its two-hundred day simple moving average is $1.54. The firm has a market capitalization of $46.02 million, a PE ratio of -4.42 and a beta of 0.56.
ABVC BioPharma (NASDAQ:ABVC – Get Free Report) last released its quarterly earnings results on Monday, May 18th. The company reported ($0.06) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in shares of ABVC BioPharma during the 3rd quarter valued at about $60,000. Citadel Advisors LLC bought a new position in shares of ABVC BioPharma in the 3rd quarter worth approximately $48,000. Finally, Geode Capital Management LLC grew its position in ABVC BioPharma by 7.7% during the fourth quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock valued at $431,000 after buying an additional 14,553 shares during the period. 11.38% of the stock is owned by hedge funds and other institutional investors.
About ABVC BioPharma
ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.
The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.